Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis Sells 2,500 Shares

Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Edwards Lifesciences Trading Up 0.8 %

EW traded up $0.59 on Monday, reaching $73.91. 5,992,934 shares of the company traded hands, compared to its average volume of 4,648,238. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market cap of $43.59 billion, a P/E ratio of 10.67, a price-to-earnings-growth ratio of 3.63 and a beta of 1.12. The firm has a fifty day simple moving average of $69.42 and a two-hundred day simple moving average of $73.90. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.59 earnings per share. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on EW. Evercore ISI reduced their price objective on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Wells Fargo & Company reduced their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price objective for the company from $82.00 to $90.00 in a research report on Monday. Barclays boosted their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. Finally, Truist Financial reaffirmed a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $79.40.

Institutional Trading of Edwards Lifesciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Edwards Lifesciences by 9.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock worth $31,571,000 after purchasing an additional 40,348 shares during the period. AIA Group Ltd lifted its holdings in Edwards Lifesciences by 91.7% during the third quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock worth $49,461,000 after buying an additional 358,556 shares during the period. RiverPark Advisors LLC boosted its position in Edwards Lifesciences by 58.1% during the 3rd quarter. RiverPark Advisors LLC now owns 20,639 shares of the medical research company’s stock valued at $1,362,000 after acquiring an additional 7,583 shares in the last quarter. Oppenheimer & Co. Inc. increased its holdings in shares of Edwards Lifesciences by 40.0% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 36,745 shares of the medical research company’s stock valued at $3,394,000 after acquiring an additional 10,492 shares during the period. Finally, Banque Cantonale Vaudoise raised its position in shares of Edwards Lifesciences by 46.9% in the 3rd quarter. Banque Cantonale Vaudoise now owns 81,111 shares of the medical research company’s stock worth $5,353,000 after acquiring an additional 25,886 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.